BioPharma Updates, June 23rd, 2025.
SciLeads’ BioPharma is updated daily, giving our clients the most current insights on biopharma organizations including Funding, Initial Public Offering, Mergers & Acquisitions, Partnerships, and more. This week’s updates are below with links to the organizations in the platform. If you don’t have BioPharma yet, start your free trial today.
Download this update:
View BioPharma updates as a PDF.
View BioPharma updates in an Excel (.XLS) format.
Funding
- Insilico Medicine (MA, USA) raised $123M in oversubscribed Series E funding to expand its AI-driven drug discovery pipeline and enhance its automated R&D capabilities.
- Juvenescence (Isle of Man, United Kingdom) raised $76M in Series B funding to advance AI-enabled therapeutics targeting age-related diseases, with plans to establish a drug development hub in Abu Dhabi.
- Actio Biosciences (CA, USA) raised $66M in Series B funding to advance its precision medicine pipeline, including ABS-1230 for KCNT1-related epilepsy and ABS-0871 for Charcot-Marie-Tooth disease type 2C and overactive bladder.
- Visby Medical (CA, USA) raised $55M in funding, with potential to reach $65M, to accelerate the launch and distribution of its FDA-authorized at-home Women’s Sexual Health Test and expand its presence in the at-home diagnostics market.
- Corvia Medical (MA, USA) raised $55M in funding to complete its RESPONDER-HF trial evaluating the Corvia® Atrial Shunt for heart failure with preserved and mildly reduced ejection fraction, supporting FDA approval efforts.
- PolyActiva (Melbourne, Australia) raised $25M in Series C funding to advance development of PA5108, a sustained-release ocular implant for glaucoma, and to support expansion into the U.S. market.
- Arima Genomics (CA, USA) raised $22M in Series C funding to accelerate the clinical rollout of its genome architecture-based oncology diagnostics platform, enhancing cancer therapy selection through its CLIA-certified Aventa testing lab.
- Materna Medical (CA, USA) raised $20M in Series B2 funding to support the upcoming FDA De Novo submission and commercialization of Ellora™, its pelvic health device aimed at reducing pelvic floor injuries during childbirth.
- Celltrio (CA, USA) raised $15M in funding to expand global commercialization of its RoboCell® automation platform for sterile cell culture and cell therapy manufacturing, and to scale operations across North America, Europe, and Asia.
- ABM Respiratory Care (MN, USA) raised $14.8M in Series B funding to expand commercialization of its BiWaze® Clear airway clearance system for hospital and home use, scale U.S. sales, and enhance digital health capabilities.
- Paradigm Therapeutics (SC, USA) raised $12.6M in funding to accelerate regulatory and manufacturing activities ahead of the global launch of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa.
- GeneCentric Therapeutics (NC, USA) raised $8M in Series C funding to support the launch of GenomicsNext™, its new liquid biopsy platform combining gene expression profiling and DNA variant detection from a single blood sample for precision oncology.
- Infinity Bio (MD, USA) raised $8M in Series A funding to expand commercialization of its immune profiling platform, MIPSA™, and launch new services like EnviroSIGHT™.
- EVerZom (Paris, France) received a $3.2M grant through France 2030 to scale up its exosome bioproduction platform and advance development of exosome-based therapies for regenerative medicine.
- RevelAi Health (NC, USA) raised $3.1M in seed funding to scale its conversational AI platform for musculoskeletal care, helping orthopedic providers streamline documentation, patient engagement, and value-based care coordination.
- Apini (Manchester, United Kingdom) raised $2.3M in funding to develop therapies targeting eNAMPT for chronic inflammatory conditions such as Crohn’s disease and Ulcerative Colitis.
- Droplet IV (Copenhagen, Denmark) raised $2M in funding to support the EU and US launch of its automated IV-line flushing device, aiming to improve medication safety and efficiency for nurses by reducing the burden of manual flushing.
- Argenica Therapeutics (Perth, Australia) received a $1.5M Medical Research Future Fund grant under Australia’s TTRA program to support late-stage clinical trials of ARG-007 in acute ischaemic stroke.
- Precisio Biotix Therapeutics (DE, USA) received a grant from the Gates Foundation of an undisclosed amount to discover engineered lysins targeting bacterial vaginosis using its AI-driven Zeus™-LysiThru™ platform.
- Pimera Therapeutics (CA, USA) received an undisclosed Medical Research Future Fund grant to expand its Phase 1a/b basket trial of PMR-116, a Pol I inhibitor targeting MYC-driven cancers, including solid tumors resistant to standard treatments.
- Neoclease (Boston, MA, USA) received the 2025 North American Advance Biotech Grant from MilliporeSigma to support development of its AI-designed gene-editing therapies for Parkinson’s disease.
Emerging
- Draig Therapeutics (Cardiff, United Kingdom) launched with $140M in funding to develop a pipeline of next-generation neuropsychiatric therapies, including Phase 2 trials of lead candidate DT-101 for Major Depressive Disorder.
- Symbiotic.blue (London, United Kingdom) launched to build a next-generation AI-driven drug discovery platform, combining brain-inspired computational models and multi-target drug design, with an initial focus on obesity.
- Demeter Bio (London, United Kingdom) emerged from stealth to develop nature-inspired, sustainable alternatives to environmentally harmful materials like PFAS, UV filters, and microplastics, aiming to reduce CO₂ emissions and ecological degradation.
Post IPO Equity
- Eyenovia, Inc. (NY, USA) raised $50M through a private placement in public equity (PIPE Financing) to acquire and stake HYPE tokens and support ongoing business operations and product development.
- Biomea Fusion (CA, USA) raised $40M through an underwritten public offering of common stock and warrants to support the development of its clinical-stage diabetes and obesity therapies.
- PolyPid (Petah Tikva, Israel) raised $26.7M through the immediate exercise of existing warrants to fund its NDA submission, launch preparations, working capital, and general corporate purposes, extending its runway beyond anticipated FDA approval of D-PLEX₁₀₀.
- Klotho Neurosciences (NE, USA) raised over $11M through the exercise of existing warrants to fully extinguish all outstanding debt, achieve a debt-free balance sheet, and regain compliance with NASDAQ stockholders’ equity requirements.
- Processa Pharmaceuticals (MD, USA) raised $7M through a public offering to continue the Phase 2 clinical trial for NCG-Cap and for working capital and general corporate purposes.
- Moleculin Biotech, Inc. (TX, USA) raised $5.9M through a public offering of common stock and warrants to advance Annamycin and other drug candidates through clinical and preclinical development, sponsor research, and support working capital.
- FibroBiologics (TX, USA) raised $5M through the third tranche of a Standby Equity Purchase Agreement to fund research and development programs, support its upcoming Phase 1/2 diabetic foot ulcer clinical trial, and for general corporate purposes.
- Alzamend Neuro (GA, USA) raised $5M through a private placement to support five Phase II clinical trials of AL001 “Lithium in Brain” studies at Massachusetts General Hospital and strengthen its financial position.
- Shuttle Pharmaceuticals (MD, USA) raised $4.25M through a securities purchase agreement to fund potential acquisitions, marketing, and general corporate purposes.
- Adial Pharmaceuticals (VA, USA) raised $3.6M through a public offering to support working capital and general corporate purposes.
- Cyclacel Pharmaceuticals (NJ, USA) raised $3M through a private placement of convertible Series F Preferred Stock and warrants to support working capital and general corporate purposes.
- SciBase (Stockholm, Sweden) raised ~$2.8M through a directed share issue to accelerate the development of an AI-based diagnostic test for predicting atopic dermatitis flares and to support its collaboration and license agreement with Castle Biosciences.
- Acurx Pharmaceuticals (NY, USA) raised $2.67M through the immediate exercise of existing warrants to support working capital and general corporate purposes.
- Psyence Group (Toronto, Canada) raised ~$440K through a non-brokered private placement to pursue potential strategic transactions, business combinations, and general working capital purposes.
- Hemostemix (Calgary, Canada) raised ~$343K through a non-brokered private placement to support general working capital, operational expenses, and business development activities.
Mergers and Acquisitions
- Concentra Biosciences (MA, USA) to acquire Elevation Oncology (MA, USA) for $0.36 per share in cash plus a contingent value right for the continued development of EO-3021.
- Harrow Health, Inc. (TN, USA) to acquire U.S. commercial rights to BYQLOVI from Formosa Pharmaceuticals (Taipei, Taiwan) for expansion of its branded ophthalmic pharmaceutical portfolio.
- A Private biotechnology company to acquire Windtree Therapeutics‘ (PA, USA) preclinical oncology drug candidate portfolio for strategic focus on cardiovascular assets.
- XtalPi (MA, USA) to acquire Liverpool ChiroChem (Liverpool, United Kingdom) to expand capabilities in chemical space exploration and accelerate drug discovery using integrated AI, robotics, and quantum physics platforms.
- BioNTech (Mainz, Germany) to acquire CureVac (Tübingen, Germany) for approximately $1.6B in a public exchange offer to strengthen infectious disease and oncology pipelines through combined mRNA technology platforms.
- Enzon Pharmaceuticals (NJ, USA) to merge with Viskase (IL, USA) for $81M for strategic expansion and diversification.
Partnerships
- NextCure, Inc. (MD, USA) and Simcere Zaiming (Shanghai, China) announced a ~$745M strategic partnership granting NextCure global rights to SIM0505 (excluding Greater China) and access to proprietary ADC technology.
- Processa Pharmaceuticals (MD, USA) and Intact Therapeutics (CA, USA) announced a ~$455M exclusive option and license agreement for PCS12852, a selective 5-HT4 receptor agonist with positive Phase 2a data in diabetic gastroparesis.
- Avata Biosciences (London, United Kingdom) and Oceanus Bio (Tokyo, Japan) announced a ~$95M co-development and licensing agreement granting Oceanus exclusive rights to AVAT-021 and AVAT-022 in Japan and Asia (excluding China and India).
- Orion (Espoo, Finland) and Glykos Finland (Finland) announced the extension of their research collaboration and licensing agreement to develop up to three additional next-generation antibody-drug conjugate (ADC) programs for solid tumors, with Glykos eligible for milestone payments and royalties.
- Teva Pharmaceuticals (Tel Aviv, Israel) and Fosun Pharma (Shanghai, China) announced a strategic partnership granting Fosun Pharma exclusive rights to develop, manufacture, and commercialize TEV-56278, an anti-PD1-IL2 ATTENUKINE™ therapy, in Greater China and select Southeast Asian countries to accelerate clinical data generation for this Phase 1 oncology candidate.
- AbTherx (CA, USA) and GPCR Therapeutics (Seoul, South Korea) announced a research collaboration to discover and develop therapeutic antibodies targeting GPCRs, leveraging AbTherx’s Atlas Long CDR3 Mouse platform with a 50/50 ownership structure and potential to expand to additional targets.
- HELP Therapeutics (Nanjing, China) and China Resource Sanjiu Medical & Pharmaceutical Co., Ltd (Guagndong, China) announced a strategic partnership to co-develop and commercialize the iPSC-derived cell therapy HiCM-188 for advanced heart failure in Mainland China.
- NRx Pharmaceuticals (DE, USA) and HOPE Therapeutics (FL, USA) announced a strategic investor relations partnership with astr partners to enhance investor communications and support their clinical and business growth strategies in neuropsychiatry therapies.
- AtomVie Global Radiopharma Inc. (Hamilton, Canada) and TerraPower (WA, USA) announced a supply agreement for high-quality Actinium-225 to support AtomVie’s CDMO activities and accelerate the development and commercialization of targeted radiopharmaceutical therapies.
- SunRock Biopharma, S.L (Spain) and Escugen (Shanghai, China) announced a strategic partnership to co-develop SRB123, a first-in-class antibody-drug conjugate targeting CCR9 in multiple solid tumors, sharing development responsibilities, joint patents, and reciprocal licensing option rights.
- Agenus (MA, USA) and Noetik (CA, USA) announced a research collaboration to develop predictive biomarkers for Agenus’ BOT/BAL immuno-oncology combination by leveraging AI-powered virtual cell models and large-scale multimodal tumor data.
- Marker Therapeutics, Inc. (TX, USA) and Cellipont Bioservices (TX, USA) announced a manufacturing collaboration for cGMP production of MT-601, Marker’s lead Multi-Antigen Recognizing T cell (MAR-T) therapy, to accelerate clinical supply and support potential pivotal trials in lymphoma patients.
- Immuno Cure (Hong Kong) and PharmaJet (CO, USA) announced a collaboration to evaluate the safety and immunogenicity of the HIV therapeutic DNA vaccine ICVAX delivered via PharmaJet’s Tropis® needle-free injection system in a new clinical study.
- MAIA Biotechnology, Inc. (IL, USA) announced a clinical master supply agreement with Roche (Switzerland) to study the combination of its telomere-targeting agent ateganosine (THIO) with Roche’s checkpoint inhibitor atezolizumab (Tecentriq®) in multiple hard-to-treat cancers.
Initial Public Offering (IPO)
- Jyong Biotech (New Taipei City, Taiwan) announced a $20M initial public offering to fund Phase III and earlier-phase trials of MCS-2, advance its clinical pipeline, and support general corporate purposes.
Registered Direct Offering (RDO)
- Aptevo Therapeutics (WA, USA) raised $8M through a registered direct offering of common stock and warrants to support continued clinical development of its product candidates, working capital, and general corporate purposes.
Closures and Layoffs
- Prothena (CA, USA) to lay off 91 employees for discontinuation of birtamimab development after Phase III trial failure
- Scorpion Therapeutics (MA, USA) to lay off certain employees for organizational resizing after spinning out assets to Antares and sale of PI3Kα program to Lilly
- Gilead Sciences (CA, USA) to lay off 36 employees for relocating biologics teams from Oceanside to Foster City
- ImmunityBio (CA, USA) to lay off 3 employees for continued workforce reduction following earlier California cuts
- Lycia Therapeutics (CA, USA) to lay off 23 employees as it advances LYTAC platform and prepares LCA-0061 and LCA-0321 for IND studies
- BioNTech (Mainz, Germany) to lay off 63 employees as it winds down cell therapy manufacturing following discontinuation of BNT211 in testicular cancer.
Is there anything else you’d love to see here or have added to the platform? Please don’t hesitate to contact us with your feedback.